As of May 31, 2025, Fennec Pharmaceuticals Inc (FENC) reports a Current Ratio of 6.38.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Fennec Pharmaceuticals Inc's Current Ratio
Over recent years, Fennec Pharmaceuticals Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 6.38 |
| 2023-12-31 | 3.56 |
| 2022-12-31 | 5.80 |
| 2021-12-31 | 13.57 |
| 2020-12-31 | 13.37 |
This slight upward trend highlights how Fennec Pharmaceuticals Inc manages its short-term assets and liabilities over time.
Comparing Fennec Pharmaceuticals Inc's Current Ratio to Peers
To better understand Fennec Pharmaceuticals Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Fennec Pharmaceuticals Inc (FENC) | 6.38 |
| Protara Therapeutics Inc (TARA) | 15.71 |
| Atossa Therapeutics Inc (ATOS) | 14.99 |
| Galecto Inc (GLTO) | 14.07 |
| Aptinyx Inc (APTX) | 10.16 |
| Concert Pharmaceuticals Inc (CNCE) | 9.33 |
Compared to its competitors, Fennec Pharmaceuticals Inc's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.